

## UNITED STATE ARTMENT OF COMMERCE Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

| APPLICATION NO. | FILING DATE | FIRST NAMED INVENTOR |   | ATTORNEY DOCKET NO. |
|-----------------|-------------|----------------------|---|---------------------|
| 087211.312      | 07/01/94    | LARTGNE              | Δ | 6600750YP           |

HM21/0428

OBLON SPIVAK MC CLELLAND MAIER & NEUSTADT 1755 JEFFERSON DAVIS HIGHWAY 4TH FLOOR ARLINGTON VA 22202 **EXAMINER**MINNIFIELD.N

ART UNIT PAPER NUMBER

DATE MAILED:

04/28/98

Please find below and/or attached an Office communication concerning this application or proceeding.

**Commissioner of Patents and Trademarks** 

## Office Action Summary

 Applicant(s)

LABIGNE ET AL

Examiner

N. M. MINNIFELD

Group Art Unit 1645

| X Responsive to communication(s) filed on <u>Feb 12, 1998</u>  |          |  |  |  |                                       |  |
|--|----------|--|--|--|---------------------------------------|--|
| ☐ This action is <b>FINAL</b> .  |          |  |  |  |                                       |  |
| ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is close in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11; 453 O.G. 213.   |          |  |  |  |                                       |  |
| A shortened statutory period for response to this action is set to expire3month(s), or thirty days, whichever is longer, from the mailing date of this communication. Failure to respond within the period for response will cause the application to become abandoned. (35 U.S.C. § 133). Extensions of time may be obtained under the provisions of 37 CFR 1.136(a). | er<br>ie |  |  |  |                                       |  |
| Disposition of Claims  |          |  |  |  |                                       |  |
| X Claim(s) 40-45 and 52-67 is/are pending in the application.  |          |  |  |  |                                       |  |
| Of the above, claim(s) is/are withdrawn from consideration   | n.       |  |  |  |                                       |  |
| ☐ Claim(s) 40-45, 53-55, and 62 is/are allowed.  |          |  |  |  |                                       |  |
|  |          |  |  |  |                                       |  |
| Claim(s) is/are objected to.   |          |  |  |  |                                       |  |
| ☐ Claims are subject to restriction or election requirement  |          |  |  |  |                                       |  |
| Application Papers   |          |  |  |  |                                       |  |
| ☐ See the attached Notice of Draftsperson's Patent Drawing Review, PTO-948.  |          |  |  |  |                                       |  |
| The drawing(s) filed on is/are objected to by the Examiner.  |          |  |  |  |                                       |  |
| ☐ The proposed drawing correction, filed on is ☐approved ☐disapproved.   |          |  |  |  |                                       |  |
| The specification is objected to by the Examiner.  |          |  |  |  |                                       |  |
| ☐ The oath or declaration is objected to by the Examiner.  |          |  |  |  |                                       |  |
| Priority under 35 U.S.C. § 119   |          |  |  |  |                                       |  |
| Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d).  All Some* None of the CERTIFIED copies of the priority documents have been  |          |  |  |  |                                       |  |
| received.  |          |  |  |  |                                       |  |
| received in Application No. (Series Code/Serial Number)  |          |  |  |  |                                       |  |
| received in his national stage application from the International Bureau (PCT Rule 17.2(a)).  *Certified copies not received:  Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e).  |          |  |  |  |                                       |  |
|  |          |  |  |  | Attachment(s)                         |  |
|  |          |  |  |  | ☐ Notice of References Cited, PTO-892 |  |
| ☐ Information Disclosure Statement(s), PTO-1449, Paper No(s)   |          |  |  |  |                                       |  |
| <ul> <li>☐ Interview Summary, PTO-413</li> <li>☐ Notice of Draftsperson's Patent Drawing Review, PTO-948</li> </ul>  |          |  |  |  |                                       |  |
| ☐ Notice of Informal Patent Application, PTO-152   |          |  |  |  |                                       |  |
|  |          |  |  |  |                                       |  |
| SEE OFFICE ACTION ON THE FOLLOWING PAGES   |          |  |  |  |                                       |  |

Serial Number: 08/211312 Page 2

Art Unit: 1645

## **DETAILED ACTION**

## Response to Amendment

- 1. EFFECTIVE FEBRUARY 7, 1998, the Group and/or Art Unit location of your application in the PTO has changed. To aid in correlating any papers for this application, all further correspondence regarding this application should be directed to Group Art Unit 1645. We are now in Technology Center 1600, Art Unit 1645.
- 2. Applicants' amendment filed February 12, 1998 is acknowledged and has been entered. Claims 40, 54 and 60 have been amended. Claims 1-17, 20-36 and 46-51 have been canceled. New claims 62-67 have been added. Claims 40-45 and 52-67 are now pending in the present application. The previous rejections have been withdrawn, in view of Applicants' amendment to the claims and comments, with the exception of those specifically discussed below.
- 3. The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.
- 4. Claims 63-67 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. The claims should recite "The purified polypeptide" rather than "A purified polypeptide" as the depend from independent claim 62 which recites "A purified polypeptide".
- 5. The specification is objected to as failing to provide proper antecedent basis for the claimed subject matter. See 37 CFR 1.75(d)(1) and MPEP § 608.01(o). Correction of the

Serial Number: 08/211312 Page 3

Art Unit: 1645

following is required: The specification does not provide support for the recitation of a "pharmaceutically acceptable carrier".

The above objection is maintained as it has not been addressed by Applicants.

6. The abstract of the disclosure is objected to because misspelled word and abstract should be directed to the claimed invention. Correction is required. See MPEP § 608.01(b).

Applicant is reminded of the proper content of an abstract of the disclosure. A patent abstract is a concise statement of the technical disclosure of the patent and should include that which is new in the art to which the invention pertains. If the patent is of a basic nature, the entire technical disclosure may be new in the art, and the abstract should be directed to the entire disclosure. If the patent is in the nature of an improvement in an old apparatus, process, product, or composition, the abstract should include the technical disclosure of the improvement. In certain patents, particularly those for compounds and compositions, wherein the process for making and/or the use thereof are not obvious, the abstract should set forth a process for making and/or use thereof. If the new technical disclosure involves modifications or alternatives, the abstract should mention by way of example the preferred modification or alternative.

The abstract should not refer to purported merits or speculative applications of the invention and should not compare the invention with the prior art.

Where applicable, the abstract should include the following:

- (1) if a machine or apparatus, its organization and operation;
- (2) if an article, its method of making;
- (3) if a chemical compound, its identity and use;
- (4) if a mixture, its ingredients;
- (5) if a process, the steps.

Extensive mechanical and design details of apparatus should not be given.

Serial Number: 08/211312 Page 4

Art Unit: 1645

Applicant is reminded of the proper language and format for an abstract of the disclosure. The abstract should be in narrative form and generally limited to a single paragraph on a separate sheet within the range of 50 to 250 words. It is important that the abstract not exceed 250 words in length since the space provided for the abstract on the computer tape used by the printer is limited. The form and legal phraseology often used in patent claims, such as "means" and "said," should be avoided. The abstract should describe the disclosure sufficiently to assist readers in deciding whether there is a need for consulting the full patent text for details.

The language should be clear and concise and should not repeat information given in the title. It should avoid using phrases which can be implied, such as, "The disclosure concerns," "The disclosure defined by this invention," "The disclosure describes," etc.

- 7. Claims 40-45, 53-55 and 62 are allowable.
- 8. Claim 52 would be allowable if the amino acid sequence were identified with a SEQ. ID.
- 9. The prior art made of record and not relied upon is considered pertinent to applicant's disclosure.
- 10. Any inquiry concerning this communication or earlier communications from the examiner should be directed to N. M. Minnifield whose telephone number is (703) 305-3394. The examiner can normally be reached on Monday-Thursday from 7:00 AM-4:30 PM. The examiner can also be reached on alternate Fridays.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Paula K. Hutzell, Ph.D., can be reached on (703) 308-3153. The fax phone number for this Group is (703) 305-3014.

Serial Number: 08/211312

Page 5

Art Unit: 1645

Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (703) 308-0196.

N. M. Minnifield

April 27, 1998

profile (